BioInvent International
28.10.2021 08:31:40 CEST | ACCESS Newswire | Press release
LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV)
"The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio. The integration of functions, on top of world leading science, makes it possible for us to develop novel treatments for patients suffering from serious diseases. The solid balance sheet and strong, loyal shareholders support us in achieving our goals," said Martin Welschof, BioInvent CEO.
Events in the quarter
• (R) BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.
• Emma Meurling joined Bioinvent as Human Resource (HR) Director.
Events after the period
• BioInvent and Transgene announced that preclinical data for BT-001, a novel oncolytic virus delivering an anti-CTLA-4 antibody for the treatment of solid tumors, will be presented at SITC in November 2021.
• New data on the lead drug candidate BI-1206 Phase 1/2a study in non-Hodgkin's lymphoma (NHL) to be presented at the ASH (American Society of Hematology) conference December 11-14.
• New production agreement with CRUK to produce additional batch of anti-HER3 antibody.
• Prof. Eggermont new member of the BioInvent Scientific Advisory Board.
Financial information
Third quarter 2021
• Net sales SEK 3.0 (16.3) million.
• Loss after tax SEK -62.6 (-32.9) million.
• Loss after tax per share before and after dilution SEK -1.07 (-1.00).
• Cash flow from operating activities -57.5 (-31.4) million.
January - September 2021
• Net sales SEK 14.5 (48.6) million.
• Loss after tax SEK -199.7 (-104.9) million.
• Loss after tax per share before and after dilution SEK -3.79 (-4.00).
• Cash flow from operating activities SEK -170.1 (-91.8) million.
• Liquid funds and long-term investments as of September 30, 2021: SEK 1,445.3 (642.1) million.
The complete report is attached as pdf and is available on the company's website www.bioinvent.com/investors/#financialreports.
(R)= Regulatory event
Contacts
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
About Us
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/670065/BioInvent-International-AB-Interim-Report-January--September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Reports Increased Engagement as Canadian Facilities Reassess Compliance Exposure Ahead of Carbon Deadlines6.5.2026 15:15:00 CEST | Press release
170% year-over-year increase in traded volumes across TIER and BC OBPS within Karbon-X's trading activity reflects accelerated procurement activity as regulated entities enter the execution phase of the 2026 compliance cycle. CALGARY, AB / ACCESS Newswire / May 6, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today reported increased engagement from regulated facilities across Canada as organizations reassess their compliance position ahead of upcoming reporting and credit surrender deadlines. This includes a 170% increase in traded volumes across TIER and BC OBPS markets within Karbon-X's trading activity compared to the prior year, reflecting increased participation as facilities move into active procurement and execution phases ahead of submission timelines. As the current compliance cycle progresses across Alberta's Technology Innovation and Emissions Red
Global Sports Brand U.S. Polo Assn. Delivers Record $2.7 Billion in Retail Sales for 2025, Targets $4 Billion and 1,500 U.S. Polo Assn. Stores6.5.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / May 6, 2026 / USPA Global, the company that manages U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), today announced that the global sports brand has delivered a record $2.7 billion in worldwide retail sales in 2025, reflecting strong momentum across global markets, channels, and product categories. U.S. Polo Assn. is advancing toward a long‑term goal of $4 billion in global retail sales and 1,500 branded stores worldwide. Record Growth and Global Momentum U.S. Polo Assn.'s 2025 record-breaking performance was driven by continued expansion across both established and emerging markets. North America, the brand's largest region, delivered steady gains, while strong momentum continued across India, the Middle East, Western Europe, and Latin America. Emerging regions, including Asia Pacific and Eastern Europe, also contributed to meaningful growth for the global multi-billion-dollar brand. India remains the bra
Case IQ Advances Its Leadership Position in AI For Investigations with Playbooks6.5.2026 10:00:00 CEST | Press release
Playbooks is a new way to guide AI toward investigative outcomes that ethics, compliance, and HR teams across the EU can trust. LONDON, GB / ACCESS Newswire / May 6, 2026 / Case IQ, the leading provider of end-to-end compliance and risk management solutions for ethics, compliance and HR teams, today announced Playbooks, a new enhancement to Clairia, its AI assistant purpose-built for investigators. Case IQ continues to raise the bar for AI in investigations with Playbooks, which brings greater consistency, control, and confidence to AI-assisted case management. Playbooks enable organizations to shape how AI supports investigators based on their own standards, policies, and operational needs. Organizations feel pressure to adopt AI for investigations, making it difficult to govern, especially while navigating different regulations and standards across EU regions/countries. It's no surprise, as AI adoption is rising: according to our recent investigative benchmark report, which surveyed
Transoft Solutions Acquires CADaptor Solutions6.5.2026 08:00:00 CEST | Press release
Transoft Solutions Expands Temporary Traffic Management Portfolio With Latest Acquisition VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Transoft Solutions, a global leader in transportation engineering, analysis, and operations software, is pleased to announce that it has acquired CADaptor Solutions Ltd, developers of temporary traffic management software. CADaptor Solutions is based out of Huddersfield, UK and was established over 30 years ago. Their CONE Software solution is used widely in the United Kingdom within the Traffic Management industry to aid in the preparation of temporary traffic control diagrams, route diversion and event management schemes. CONE covers all aspects of temporary traffic management design from simple pedestrian footways through to complex multi-lane highway closures and contra-flows. It is used by wide variety of traffic planning related professionals including Highways Agencies, Utility Companies, Local Government, Traffic Management Companies, Civil E
Lawline Exits Beta and Launches Full AI Legal Platform for Businesses and Individuals5.5.2026 15:00:00 CEST | Press release
Sweden's most visited legal platform, recognised among the Nordics' top 9 AI legal startups alongside Legora and others, moves out of beta after surpassing 7,000 registered users, expanding its offering for companies, organisations, and individuals. STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Lawline, Sweden's most visited legal platform, today announced the official launch of its AI-driven legal platform, marking its transition out of beta. The launch introduces a significantly expanded product offering aimed at businesses, organisations, and individuals seeking accessible, reliable legal support in everyday decision-making. Lawline AI was first released in beta in February 2026 and has since attracted more than 7,000 registered users. With today's full launch, Lawline introduces a broader suite of capabilities designed to bring legal support closer to where decisions are actually made. "Legal support has traditionally been something you access after the fact, often when problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom